A novel companion diagnostic predicts response to the PARP inhibitor rucaparib in ovarian cancer

This article has no abstract
Epistemonikos ID: 46d3521d9acfc8e5b6ea66269abf4ddb369b050d
First added on: Feb 07, 2025